ClinConnect ClinConnect Logo
Search / Trial NCT06103903

Measure of Acceptance of chRonic Visible sKin conditionS

Launched by UNIVERSITY HOSPITAL, TOURS · Oct 24, 2023

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Chronic Dermatological Disease Psychology Sociology Disease Acceptance Vitiligo Port Wine Stain Hyperpigmentation Alopecia Areata

ClinConnect Summary

This clinical trial is focused on understanding how people feel about living with visible chronic skin conditions, such as port wine stains, alopecia areata, vitiligo, and hyperpigmentation. The goal is to test four different questionnaires that will help researchers learn more about patients' acceptance of these conditions and how it affects their mental well-being and social interactions. The study will include a wide range of participants, including children as young as six, adults, and their parents, to ensure that the findings reflect different experiences and perspectives.

To participate, individuals need to have one of the specified skin conditions, and they must be open to sharing their experiences. Parents of affected children or young adults living at home are also welcome to join. Participants will be asked to complete the questionnaires, which will help researchers gather valuable information about the emotional and social impacts of these skin conditions. It's important to note that people with certain other skin issues or significant psychiatric disorders will not be eligible for this study. This trial is currently recruiting participants, and being part of it could help improve understanding and support for those living with visible skin conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Targeted pathologies:
  • Flat angioma
  • Primary hypopigmentation and early vitiligo
  • Primary hyperpigmentation
  • Refractory alopecia areata or congenital alopecia
  • 2. Persons concerned:
  • Children (≥ 6 years old) suffering from one of the aforementioned pathologies
  • Adults suffering from one of the above-mentioned pathologies
  • Parents of children suffering from one of the aforementioned pathologies
  • Parents of young adult patients if they live under the same roof
  • 3. Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor)
  • Exclusion Criteria:
  • 1. Secondary "marks" (post-inflammatory, post-medication, post-traumatic, etc.)
  • 2. Major psychiatric disorders

About University Hospital, Tours

The University Hospital of Tours, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative clinical research and patient-centered care. With a strong emphasis on collaboration between researchers, clinicians, and community partners, the hospital fosters a dynamic environment for conducting high-quality clinical trials across various medical disciplines. Its commitment to excellence in patient safety, ethical standards, and scientific integrity positions the University Hospital of Tours as a pivotal contributor to the development of new therapies and health solutions, ultimately enhancing patient outcomes and public health.

Locations

Tours, , France

Patients applied

0 patients applied

Trial Officials

Annabel MARUANI, MD-PhD

Study Director

University Hospital of TOURS

Jean-Benoit HARDOUIN, MD-PhD

Study Chair

INSERM UMR 1246 SPHERE

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported